{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T16:54:00Z","timestamp":1783875240181,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","content-domain":{"domain":["patient-research.elsevier.com","thespinejournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Spine Journal"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.spinee.2013.11.046","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T20:30:36Z","timestamp":1386361836000},"page":"e29-e35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Vertebral compression fractures in patients under treatment with denosumab: a contraindication for percutaneous vertebroplasty?"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8024-7094","authenticated-orcid":false,"given":"Tobias A.","family":"Mattei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehud","family":"Mendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Bourekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.spinee.2013.11.046_bib1","first-page":"89","article-title":"Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors","volume":"6","author":"Brown-Glaberman","year":"2012","journal-title":"Biologics"},{"key":"10.1016\/j.spinee.2013.11.046_bib2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1634\/theoncologist.2010-0154","article-title":"The role of RANK-ligand inhibition in cancer: the story of denosumab","volume":"16","author":"Castellano","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.spinee.2013.11.046_bib3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5312\/wjo.v4.i4.207","article-title":"RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases","volume":"4","author":"Yasuda","year":"2013","journal-title":"World J Orthop"},{"key":"10.1016\/j.spinee.2013.11.046_bib4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10555-006-9021-3","article-title":"The RANK\/RANKL\/OPG triad in cancer-induced bone diseases","volume":"25","author":"Dougall","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.spinee.2013.11.046_bib5","first-page":"268","article-title":"The OPG\/RANKL\/RANK system in metabolic bone diseases","volume":"4","author":"Hofbauer","year":"2004","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.spinee.2013.11.046_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/11598090-000000000-00000","article-title":"Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours","volume":"51","author":"Gibiansky","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.spinee.2013.11.046_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cnm.2584","article-title":"Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab","volume":"30","author":"Scheiner","year":"2014","journal-title":"Int J Numer Method Biomed Eng"},{"key":"10.1016\/j.spinee.2013.11.046_bib8","first-page":"47","article-title":"The contribution of cortical and trabecular tissues to bone strength: insights from denosumab studies","volume":"10","author":"Iolascon","year":"2013","journal-title":"Clin Cases Miner Bone Metab"},{"key":"10.1016\/j.spinee.2013.11.046_bib9","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00198-011-1724-9","article-title":"Prevalence of osteoporosis among cancer patients in Germany: prospective data from an oncological rehabilitation clinic","volume":"23","author":"Reuss-Borst","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.spinee.2013.11.046_bib10","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archinte.165.5.552","article-title":"Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study","volume":"165","author":"Chen","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.spinee.2013.11.046_bib11","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1007\/s00198-011-1870-0","article-title":"European Society for Clinical Economical Aspects of Osteoporosis and Osteoarthritis (ESCEO) guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper","volume":"23","author":"Rizzoli","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.spinee.2013.11.046_bib12","first-page":"3551","article-title":"Osteoporosis and fractures after androgen deprivation initiation for prostate cancer","volume":"14","author":"Malcolm","year":"2007","journal-title":"Can J Urol"},{"key":"10.1016\/j.spinee.2013.11.046_bib13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spinee.2013.11.046_bib14","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.spinee.2013.11.046_bib15","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1007\/s00198-013-2530-3","article-title":"Cancer-associated bone disease","volume":"24","author":"Rizzoli","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.spinee.2013.11.046_bib16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.spinee.2013.11.046_bib17","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spinee.2013.11.046_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.spinee.2013.11.046_bib19","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of 3 or 6 years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension","volume":"98","author":"Bone","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.spinee.2013.11.046_bib20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40258-013-0047-8","article-title":"Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US","volume":"11","author":"Parthan","year":"2013","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.spinee.2013.11.046_bib21","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1093\/annonc\/mds175","article-title":"Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid","volume":"23","author":"Vadhan-Raj","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.spinee.2013.11.046_bib22","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1158\/0008-5472.CAN-12-0044","article-title":"RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis","volume":"72","author":"Palafox","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.spinee.2013.11.046_bib23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature09387","article-title":"Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer","volume":"468","author":"Schramek","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.spinee.2013.11.046_bib24","series-title":"ClinicalTrials.gov","article-title":"Study of denosumab as adjuvant treatment for women with high risk early breast cancer receiving neoadjuvant or adjuvant therapy (D-CARE)","year":"2013"},{"key":"10.1016\/j.spinee.2013.11.046_bib25","series-title":"ClinicalTrials.gov","article-title":"Study to determine treatment effects of denosumab in patients with breast cancer receiving aromatase inhibitor therapy","year":"2013"},{"key":"10.1016\/j.spinee.2013.11.046_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.spinee.2013.11.046_bib27","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.27789","article-title":"Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid","volume":"119","author":"Cleeland","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.spinee.2013.11.046_bib28","doi-asserted-by":"crossref","first-page":"E373","DOI":"10.36076\/ppj.2011\/14\/E373","article-title":"Painful osseous metastases","volume":"14","author":"Smith","year":"2011","journal-title":"Pain Physician"},{"key":"10.1016\/j.spinee.2013.11.046_bib29","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1097\/BRS.0b013e3181b77895","article-title":"Percutaneous techniques in the treatment of spine tumors: what are the diagnostic and therapeutic indications and outcomes?","volume":"34","author":"Mendel","year":"2009","journal-title":"Spine"},{"key":"10.1016\/j.spinee.2013.11.046_bib30","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3171\/spi.2005.2.4.0436","article-title":"Percutaneous vertebroplasty and kyphoplasty performed at a cancer center: refuting proposed contraindications","volume":"2","author":"Hentschel","year":"2005","journal-title":"J Neurosurg Spine"}],"container-title":["The Spine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152994301301961X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152994301301961X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T03:29:55Z","timestamp":1647660595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152994301301961X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S152994301301961X"],"URL":"https:\/\/doi.org\/10.1016\/j.spinee.2013.11.046","relation":{},"ISSN":["1529-9430"],"issn-type":[{"value":"1529-9430","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vertebral compression fractures in patients under treatment with denosumab: a contraindication for percutaneous vertebroplasty?","name":"articletitle","label":"Article Title"},{"value":"The Spine Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.spinee.2013.11.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}